Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the Company) has announced the pricing of its secondary public offering of an aggregate of 8,000,000 shares of the Company’s common stock by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC (together, the Selling Shareholders) at a public offering price of US$31.00 per share. The Selling Shareholders have granted the underwriter a 30-day option to purchase an additional 1,200,000 shares of Common Stock from the Selling Shareholders at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 1, 2024, subject to customary closing conditions.
Latham & Watkins is advising Harmony Biosciences in the offering with a capital markets team led by Chicago partners Christopher Lueking and Jonathan Sarna, with associates KC Sands, Ryan Hudson, Teddy Finneran, and Tayler Daniels. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards, Bay Area partner Betty Pang, and Washington, D.C. counsel Chad Jennings; and on tax matters by Chicago partner Rene de Vera.
